David Goel Matrix Capital Management Company
David Goel is a co-founder of Matrix Capital Management, a technology-oriented investment firm with public and private market activities. Matrix is known for concentrated positions in software, semiconductor, and internet-related businesses. Goel’s filings are monitored for high-conviction technology themes.
Top Buys
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MAZE
Maze Therapeutics
MAZE
|
+$40.3M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$21.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Aura Biosciences
AURA
$809M
| $37.7M | 65.48% |
6,922,870
| – | – |
|
|
MAZE
2
Maze Therapeutics
MAZE
$1.63B
| $19.9M | 34.52% |
480,000
-1,173,684
| -71% | -$40.3M |
|
|
3
Zentalis Pharmaceuticals
ZNTL
$363M
| – | – |
-13,959,973
| Closed | -$21.1M |
|
Similar funds
David Goel's Q4 2025 Portfolio in Review
As of Q4 2025, David Goel held 3 positions worth $57.6M, down 46% from $107M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
David Goel withdrew a net $61.4M in Q4 2025, closing 1 position and reducing 1 holding. Its most notable exit was Zentalis Pharmaceuticals, an estimated $21.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- David Goel's biggest Q4 2025 reduction was Maze Therapeutics, cutting an estimated $40.3M.
- David Goel fully exited Zentalis Pharmaceuticals in Q4 2025, selling an estimated $21.1M.
- David Goel's ten largest holdings make up 100% of its $57.6M portfolio in Q4 2025.
- David Goel opened 0 new positions and closed 1 in Q4 2025.
- David Goel's portfolio value fell 46% quarter-over-quarter to $57.6M.
Based on Matrix Capital Management Company's 13F filing for Q4 2025, filed 13 Feb 2026.